Literature DB >> 23076341

Emergence of pneumococcal 19A empyema in UK children.

Matthew F Thomas1, Carmen L Sheppard, Malcolm Guiver, Mary P E Slack, Robert C George, Russell Gorton, James Y Paton, Clare Simmister, David Cliff, Mohamed A Elemraid, Julia E Clark, Stephen P Rushton, David Anthony Spencer.   

Abstract

INTRODUCTION: Invasive pneumococcal disease due to serotype 19A has become a major concern, particularly in the USA and Asia. We describe the characteristics of pneumococcal serotype 19A related empyema and changes in its incidence in the UK.
METHODS: Data from paediatric empyema patients between September 2006 and March 2011 were collected from 17 respiratory centres in the UK. Pneumococcal serotypes were identified as part of the Health Protection Agency enhanced paediatric empyema surveillance programme.
RESULTS: Four serotypes accounted for over 80% of 136 cases (Serotype 1 : 43%, 3 : 21%, 7 : 11% and 19A:10%). The incidence of empyema due to serotype 19A quadrupled from 0.48 (0.16-1.13) cases per million children in 2006/2007 to 2.02 (1.25-3.09) in 2010/2011. Severity of disease was significantly increased in children with 19A infection when compared to other serotypes.
CONCLUSIONS: The incidence of empyema due to pneumococcal serotype 19A infection has increased significantly and is associated with substantial morbidity.

Entities:  

Mesh:

Year:  2012        PMID: 23076341     DOI: 10.1136/archdischild-2012-301790

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  9 in total

1.  Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines.

Authors:  Carmen Muñoz-Almagro; Adoracion Navarro-Torne; Roman Pallares
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

2.  Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.

Authors:  Wanatpreeya Phongsamart; Somporn Srifeungfung; Tanittha Chatsuwan; Pongpun Nunthapisud; Vipa Treerauthaweeraphong; Pimpha Rungnobhakhun; Sirintip Sricharoenchai; Kulkanya Chokephaibulkit
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.

Authors:  Andrew D Wiese; Marie R Griffin; Yuwei Zhu; Edward F Mitchel; Carlos G Grijalva
Journal:  Vaccine       Date:  2016-11-07       Impact factor: 3.641

Review 4.  Current concepts in host-microbe interaction leading to pneumococcal pneumonia.

Authors:  Joshua Vernatter; Liise-anne Pirofski
Journal:  Curr Opin Infect Dis       Date:  2013-06       Impact factor: 4.915

Review 5.  Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology.

Authors:  M A Fletcher; H-J Schmitt; M Syrochkina; G Sylvester
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-23       Impact factor: 3.267

Review 6.  Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2016-12-25       Impact factor: 5.923

7.  Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.

Authors:  Catarina Silva-Costa; Maria João Brito; Marcos D Pinho; Ana Friães; Sandra I Aguiar; M Ramirez; Jose Melo-Cristino
Journal:  Emerg Infect Dis       Date:  2018-07       Impact factor: 6.883

Review 8.  Fever in Children: Pearls and Pitfalls.

Authors:  Egidio Barbi; Pierluigi Marzuillo; Elena Neri; Samuele Naviglio; Baruch S Krauss
Journal:  Children (Basel)       Date:  2017-09-01

9.  Etiology of parapneumonic effusion and pleural empyema in children. The role of conventional and molecular microbiological tests.

Authors:  Katarzyna Krenke; Ewa Sadowy; Edyta Podsiadły; Waleria Hryniewicz; Urszula Demkow; Marek Kulus
Journal:  Respir Med       Date:  2016-05-10       Impact factor: 3.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.